Telapristone acetate: all 35 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsTerminatedNCT02811159Phase 2Results posted
• Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine FibroidsCompletedNCT02323646Phase 2Results posted
• Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing MastectomyCompletedNCT02314156Phase 2Results posted
• A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsCompletedNCT02301897Phase 2Results posted
• Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisCompletedNCT01728454Phase 2Results posted
• Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine FibroidsCompletedNCT01451424Phase 2Results posted
• Determination of the Lowest, Safe and Effective Dose of ProellexCompletedNCT01187043Phase 1/2Results posted
• Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine FibroidsTerminatedNCT01069120Phase 3Results posted
• An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 ExtTerminatedNCT00958893Phase 2Results posted
• Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension StudyTerminatedNCT00958412Phase 2Results posted
• Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003CompletedNCT00958334Phase 2Results posted
• Study to Evaluate Menses Induction in Women Administered ProellexTerminatedNCT00881608Phase 1Results posted
• Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00853567Phase 3Results posted
• Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy FemalesTerminatedNCT00787618Phase 1/2Results posted
• Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00785356Phase 3Results posted
• Crossover Study of the Safety and PK Properties of Proellex®CompletedNCT00749879Phase 1Results posted
• Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female SubjectsCompletedNCT00741468Phase 1Results posted
• Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy AdultsCompletedNCT00741273Phase 1Results posted
• Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine FibroidsTerminatedNCT00737282Phase 3Results posted
• Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00735553Phase 3Results posted
• Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00702702Phase 3Results posted
• Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00683917Phase 2Results posted
• Proellex® Pharmacokinetic Bridging Study IICompletedNCT00620503Phase 1Results posted
• A Safety and Pharmacokinetic Study of Proellex®CompletedNCT00619385Phase 1Results posted
• Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic EndometriosisTerminatedNCT00556075Phase 2Results posted
• Comparison of Two Formulations of Proellex for Oral AdministrationCompletedNCT02141061Phase 1
• Open-Label Extension Study to ZPE-202WithdrawnNCT01961908Phase 2
• Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast CancerStatus unknownNCT01800422Phase 2
• Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200CompletedNCT01739621Phase 2
• Extension of Study ZPV-200CompletedNCT01631903Phase 2
• A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic LeiomyomataCompletedNCT01069094Phase 1/2
• Proellex Pharmacokinetics Bridging StudyCompletedNCT01067807Phase 1
• Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsCompletedNCT00882258Phase 2
• Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy FemalesCompletedNCT00881062Phase 1
• Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid SymptomsWithdrawnNCT00874302Phase 3

← Telapristone acetate overview